Cor Vasa 2016, 58(5):648-652 | DOI: 10.33678/cor.2016.035

Lipertance - jeden krok v léčbě kardiovaskulárního rizika, aneb nikdy to nebylo jednodušší

MUDr. Zuzana Zafarová

Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Lipertance - jeden krok v léčbě kardiovaskulárního rizika, aneb nikdy to nebylo jednodušší. Cor Vasa. 2016;58(5):648-652. doi: 10.33678/cor.2016.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. M. Thoenes, P. Bramlage, S. Zhong, et al., Hypertension control and cardiometabolic risk: a regional perspective, Cardiology Research and Practice 2012 (2012) 925046. Go to original source... Go to PubMed...
    2. R. Jackson, C.M. Lawes, D.A. Bennett, et al., Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk, Lancet 365 (2005) 434-441. Go to original source...
    3. G. Mancia, G. De Backer, A. Dominiczak, et al., 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 25 (2007) 1105-1187. Go to original source... Go to PubMed...
    4. N.J. Wald, M.R. Law, A strategy to reduce cardiovascular disease by more than 80%, BMJ 326 (2003) 1419-1423. Go to original source... Go to PubMed...
    5. B.M. Egan, J. Li, S. Qanungo, T.E. Wolfman, Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010, Circulation 128 (2013) 29-41. Go to original source... Go to PubMed...
    6. B. Nussbaumerová, H. Rosolová, O. Mayer jr., et al. Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys), Cor et Vasa 56 (2014) e98-e104. Go to original source...
    7. B.L. Van Wijk, O.H. Klungel, E.R. Heerdink, A. de Boer, Rate and determinants of 10-year persistence with antihypertensive drugs, Journal of Hypertension 23 (2005) 2101-2107. Go to original source... Go to PubMed...
    8. F.Z. Kettani, A. Dragomir, R. Côté, et al., Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention, Stroke 40 (2009) 213-220. Go to original source... Go to PubMed...
    9. R. Chowdhury, et al. European Heart Journal 34 (2013) 2840-2948. Go to original source...
    10. R.H. Chapman, J.S. Benner, A.A. Petrilla, et al., Predictors of adherence with antihypertensive and lipid-lowering therapy, Archives of Internal Medicine 165 (2005) 1147-1152. Go to original source... Go to PubMed...
    11. S. Bangalore, G. Kamalakkannan, S. Parkar, F.H. Messerli, Fixed-dose combinations improve medication compliance: a meta-analysis, Journal of Clinical Hypertension 8 (Suppl. A) (2006) P-157 (poster). Go to original source... Go to PubMed...
    12. R. Plakogiannis, H. Cohen, D. Taft, Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia, American Journal of Health-System Pharmacy 62 (2005) 2491-2494. Go to original source... Go to PubMed...
    13. Y. Sirenko, et al. American Journal of Cardiovascular Drugs 2016.
    14. P.S. Sever, B. Dahlöf, N.R. Poulter, et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial, Lancet 361 (2003) 1149-1158. Go to original source... Go to PubMed...
    15. P. Sever, B. Dahlöf, N. Poulter, et al., Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial, European Heart Journal 27 (2006) 2982-2988. Go to original source... Go to PubMed...
    16. M. Bertrand, J-J Mourad, Combining perindopril with a calcium channel blocker and a lipid lowering agent significantly decreases mortality: a subgroup analysis of EUROPA, Circulation 128 (22 suppl.) (2013) Abstract A18906.
    17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 344 (1994) 1383-1389.
    18. R. Collins, J. Armitage, S. Parish, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet 361 (2003) 2005-2016. Go to original source...
    19. S.M. Haffner, C.M. Alexander, T.J. Cook, et al., Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 159 (1999) 2661-2667. Go to original source... Go to PubMed...
    20. P. Amarenco, J. Labreuche, P. Lavallée, P.J. Touboul, Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis, Stroke 35 (2004) 2902-2909. Go to original source... Go to PubMed...
    21. J.C. LaRosa, S.M. Grundy, D.D. Waters, et al., Intensive lipid lowering with atorvastatin in patients with stable coronary disease, New England Journal of Medicine 352 (2005) 1425-1435. Go to original source... Go to PubMed...
    22. P.S. Phillips, R.H. Haas, S. Bannykh, et al. Statin-associated myopathy with normal creatine kinase levels, Annals of Internal Medicine 137 (2002) 581-585. Go to original source... Go to PubMed...
    23. D. Rosenbaum, J. Dallongeville, P. Sabouret, E. Bruckert, Discontinuation of statin therapy due to muscular side effects: a survey in real life, Nutrition, Metabolism and Cardiovascular Diseases 23 (2013) 871-875. Go to original source... Go to PubMed...
    24. D.M. Black, R.G. Bakker-Arkema, J.W. Nawrocki, An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor, Archives of Internal Medicine 158 (1998) 577-584. Go to original source... Go to PubMed...
    25. D.D. Waters, J.E. Ho, D.A. DeMicco, et al., Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials, Journal of the American College of Cardiology 57 (2011) 1535-1545. Go to original source... Go to PubMed...
    26. C. Baigent, A. Keech, P.M. Kearney, et al., Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins, Lancet 366 (2005) 1267-1278. Go to original source...
    27. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010) 1670-1681. Go to original source... Go to PubMed...
    28. J. Filipovský, J. Widimský jr., J. Ceral, et al., Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi, Hypertenze & kardiovaskulární prevence 3 (2012) 1-16.
    29. W.J. Elliott, P.M. Meyer, Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis, Lancet 369 (2007) 201-207. Go to original source... Go to PubMed...
    30. A.M. Sharma, T. Pischon, S. Hardt, et al., Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis, Hypertension 37 (2001) 250-254. Go to original source... Go to PubMed...
    31. B. Pitt, C. Pepine, B.J. O'Neill, et al., Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low density lipoprotein cholesterol (abstr). Journal of the American College of Cardiology 29 (Suppl. A) (1997) 70A.
    32. R.C. Webb, et al. Ann Arbor 1992.
    33. X. Zhang, M.R. Kichuk, S. Mital, et al., Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts, American Journal of Cardiology 84 (1999) 27L-33L. Go to original source... Go to PubMed...
    34. T.J. Anderson, I.T. Meredith, A.C. Yeung, et al., The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, New England Journal of Medicine 332 (1995) 488-493. Go to original source... Go to PubMed...
    35. S. Nissen, E.M. Tuzcu, P. Schoenhagen, et al., Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA 291 (2004) 1071-1080. Go to original source... Go to PubMed...
    36. B. Pitt, R.P. Byington, C.D. Furberg, et al., Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators, Circulation 102 (2000) 1503-1510. Go to original source... Go to PubMed...
    37. N. Bruining, S. de Winter, J.R. Roelandt, et al., Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies, Coronary Artery Disease 20 (2009) 409-414. Go to original source... Go to PubMed...
    38. C.M. Ballantyne, Low-density lipoproteins and risk for coronary artery disease, American Journal of Cardiology 82 (1998) 3Q-12Q. Go to original source... Go to PubMed...
    39. P. Verdecchia, G. Reboldi, F. Angeli, et al., Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention, Hypertension 46 (2005) 386-392. Go to original source... Go to PubMed...
    40. K.A. Jamerson, et al., ACCOMPLISH (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension), American Journal of Hypertension 16 (part 2) (2003) 193A. Go to original source...
    41. M. Bertrand, R. Ferrari, W.J. Remme, et al., Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study, American Heart Journal 159 (2010) 795-802. Go to original source... Go to PubMed...
    42. SPC Lipertance. www.sukl.cz

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes